MRNS News and Press, Marinus Pharmaceuticals Inc. From 09/04/23

2023-09-04 14:38:18 ET Summary Marinus Pharmaceuticals received FDA approval for Ztalmy to treat seizures; aims to broaden its application. Marinus has strong financial standing with a cash runway until late 2024; ongoing trials on Ztalmy show potential. Recommendation: Mainta...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host a hybrid Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Time in New York. The event wi...

2023-08-15 17:55:10 ET Gainers: DLocal  ( DLO ) +32% . Prime Number Acquisition  ( PNAC ) +5% . Telos  ( TLS ) +5% . Marinus Pharmaceuticals ( MRNS ) +5% . Nkarta ( NKTX ) +5% . Losers: Jet.AI  ( JTA...

2023-08-10 12:20:08 ET Marinus Pharmaceuticals, Inc. (MRNS) Q2 2023 Earnings Conference Call August 10, 2023 08:30 A.M. ET Company Participants Sonia Weigle - SVP, IR, HR, and Corporate Affairs Scott Braunstein - Chairman and CEO Christy Shafer - CCO Joseph H...

2023-08-10 07:14:38 ET Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q2 GAAP EPS of -$0.61 beats by $0.10 . Revenue of $6.08M (+237.8% Y/Y) beats by $0.34M . Cash runway expected into second half of 2024 with cash, cash equivalents and short-term inve...

ZTALMY ® (ganaxolone) second quarter net product revenue of $4.2 million; 2023 net product revenue guidance increased to between $17 and $18.5 million European Commission approved ZTALMY in CDKL5 deficiency disorder Interim analysis for the Phase 3 refractory status epilepticus t...

2023-08-09 12:05:45 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q2 earnings results on Thursday, August 10th, before market open. The consensus EPS Estimate is -$0.71 and the consensus Revenue Estimate is $5.74M (+218.9% Y/Y). Over the last 1 y...

2023-07-31 16:54:37 ET Marinus Pharmaceuticals ( NASDAQ: MRNS ) and partner Orion Oyj ( OTCPK:ORINY ) said that the European Commission has granted market approval for Marinus's drug Ztalmy as an adjunctive treatment for epileptic seizures in children with CDKL5 deficiency disor...

ZTALMY is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to tre...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will ...